5G-EMERALD: Amivantamab in Malignant Brain Tumours

Clinical trial NCT06632236 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06632236
Sponsor: Institute of Cancer Research, United Kingdom
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Primary Gliomas Glioblastoma Multiform (Grade IV Astrocytoma)Diffuse Hemispheric Glioma, H3 G34-Mutant Glioblastoma Multiforme (GBM)

Start date: 2024-10-09
Primary completion: 2027-07-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.